ClinicalTrials.gg

Program

rocakinogene sifuplasmid

Also written as “INO-9012”, “INO-9112” and “INO-4212 + INO-9012”.

Its studies are mostly in Glioblastoma · Carcinoma, Transitional Cell · Hepatitis B · Hemorrhagic Fever, Ebola · Breast Neoplasms, led by 2 companies.

Furthest: phase 2, since Apr 2, 20188 company-led studies, 3 open or runningNext primary completion: Dec 31, 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Inovio Pharmaceuticals61 open or runningphase 2since Apr 2, 2018Sep 11, 2014Dec 31, 2027phase 2 · NCT03491683
Geneos Therapeutics22 open or runningphase 2since Jan 27, 2020Jan 27, 2020Sep 2029phase 2 · NCT07722741

Also a collaborator on its studies: geneone-life-science-inc.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Sep 11, 2014First study: phase 1 study in NeoplasmsNew to Inovio PharmaceuticalsInovio Pharmaceuticals · NCT02241369 · 3 enrolled · United States
  2. Apr 21, 2015Phase 1 study in Hepatitis BInovio Pharmaceuticals · NCT02431312 · 90 enrolled · United States, Australia, Hong Kong and more
  3. May 28, 2015Phase 1 study in Hemorrhagic Fever, EbolaInovio Pharmaceuticals · NCT02464670 · 240 enrolled · United States
  4. Nov 4, 2016Phase 1 study in Breast NeoplasmsInovio Pharmaceuticals · NCT02960594 · 93 enrolled · United States
  5. Apr 2, 20182 phase 2 studiesInovio Pharmaceuticals · NCT03491683, NCT03502785
  6. Jan 27, 2020Geneos Therapeutics's first study: phase 2 study in HCCNew to Geneos TherapeuticsGeneos Therapeutics · NCT04251117 · 36 enrolled · United States, New Zealand
  7. Jul 20, 2026Phase 2 study in HCCGeneos Therapeutics · NCT07722741 · 90 planned · United States, New Zealand
  8. Oct 22, 2026Primary completion moved from 2026-12-31 to 2027-12-31Date moved laterphase 2 · +12 months · NCT03491683

Ahead

  1. Dec 31, 2027Primary completion: phase 2 study in GlioblastomaInovio Pharmaceuticals · NCT03491683
  2. Sep 2029Primary completion: phase 2 study in HCCGeneos Therapeutics · NCT07722741

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 8 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07722741HCC · United States, New Zealand2RecruitingGeneos TherapeuticsSep 202990
NCT04251117HCC · United States, New Zealand2Active, not recruitingGeneos TherapeuticsNov 29, 202436
NCT03502785Carcinoma, Transitional Cell · United States2CompletedInovio PharmaceuticalsMay 9, 202535
NCT03491683Glioblastoma · United States2Active, not recruitingInovio PharmaceuticalsDec 31, 202752
NCT02960594Breast Neoplasms · United States1CompletedInovio PharmaceuticalsNov 9, 201893
NCT02464670Hemorrhagic Fever, Ebola · United States1CompletedInovio PharmaceuticalsMay 24, 2018240
NCT02431312Hepatitis B · United States, Australia, Hong Kong and more1CompletedInovio PharmaceuticalsMay 22, 201890
NCT02241369Neoplasms · United States1CompletedInovio PharmaceuticalsSep 20183

How it is read

Names in the registry

  • “INO-9012”, 5 entries
  • “INO-9112”, 1 entry
  • “INO-4212 + INO-9012”, 1 entry
  • “INO-4201 + INO-9012”, 1 entry
  • “INO-3106, INO-9012”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.